2-(3-methyl-1,2,4-oxadiazol-5-yl)acetic acid
![]() |
- $210.8 - $1563
- Product name: 2-(3-methyl-1,2,4-oxadiazol-5-yl)acetic acid
- CAS: 55151-91-2
- MF: C5H6N2O3
- MW: 142.11
- EINECS:
- MDL Number:MFCD13705349
- Synonyms:2-(3-methyl-1,2,4-oxadiazol-5-yl)acetic acid;(3-Methyl-[1,2,4]Oxadiazol-5-Yl)-Acetic Acid;1,2,4-Oxadiazole-5-acetic acid, 3-methyl-
4 prices
Selected condition:
Brand
- AK Scientific
- Crysdot
- TRC
Package
- 100mg
- 1g
- 5g
- ManufacturerAK Scientific
- Product number4964AQ
- Product description2-(3-methyl-1,2,4-oxadiazol-5-yl)aceticacid
- Packaging100mg
- Price$210.8
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11105763
- Product description2-(3-Methyl-1,2,4-oxadiazol-5-yl)aceticacid 95+%
- Packaging1g
- Price$520
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11105763
- Product description2-(3-Methyl-1,2,4-oxadiazol-5-yl)aceticacid 95+%
- Packaging5g
- Price$1563
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberM222845
- Product description(3-Methyl-[1,2,4]oxadiazol-5-yl)-aceticAcid
- Packaging100mg
- Price$220
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 4964AQ | 2-(3-methyl-1,2,4-oxadiazol-5-yl)aceticacid | 100mg | $210.8 | 2021-12-16 | Buy |
Crysdot | CD11105763 | 2-(3-Methyl-1,2,4-oxadiazol-5-yl)aceticacid 95+% | 1g | $520 | 2021-12-16 | Buy |
Crysdot | CD11105763 | 2-(3-Methyl-1,2,4-oxadiazol-5-yl)aceticacid 95+% | 5g | $1563 | 2021-12-16 | Buy |
TRC | M222845 | (3-Methyl-[1,2,4]oxadiazol-5-yl)-aceticAcid | 100mg | $220 | 2021-12-16 | Buy |
Properties
Boiling point :340.5±44.0 °C(Predicted)
Density :1.387±0.06 g/cm3(Predicted)
pka :3.34±0.10(Predicted)
Density :1.387±0.06 g/cm3(Predicted)
pka :3.34±0.10(Predicted)
Safety Information
Symbol(GHS): |
![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|